Analyst Price Target is $67.50
▲ +9,275.00% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Bone Biologics in the last 3 months. The average price target is $67.50, with a high forecast of $67.50 and a low forecast of $67.50. The average price target represents a 9,275.00% upside from the last price of $0.72.
Current Consensus is
The current consensus among 1 investment analysts is to buy stock in Bone Biologics. This Buy consensus rating has held steady for over two years.
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with degenerative disc disease at one level from L2-S1. The company's platform technology is used in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.